

## ALPHA2DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS

This application claims the benefit of U.S. Provisional Application Serial No.  
 60/433,491, filed December 13, 2002, and U.S. Provisional Application Serial No.  
 60/487, 740 filed July 16, 2003; ~~and is a Continuation-In-Part of U.S. Application~~  
 10/674,192, filed September 29, 2003, ~~which is a continuation of U.S. Application~~  
 Serial No. 10/324,929 filed December 20, 2002, now U.S. Patent 6,642,398 which  
 is a continuation of U.S. Application Serial No. 10/009,938 filed December 10,  
 2001, now abandoned, which is a 371 filing of PCT/US00/15070 filed May 31,  
 2000, which claims the benefit of U.S. Provisional Application 60/138,485 filed  
 June 10, 1999, the entire contents of which applications are hereby incorporated  
 herein by reference.

## BACKGROUND OF THE INVENTION

This invention relates to the use of certain alpha2delta ligand for the  
 treatment of fibromyalgia and other central nervous system disorders.  
 Fibromyalgia (FM) is a chronic syndrome characterized mainly by widespread  
 pain, unrefreshing sleep, disturbed mood, and fatigue. The main symptoms  
 fibromyalgia include pain, sleep, mood disturbances and fatigue. Syndromes  
 commonly associated with fibromyalgia include irritable bowel syndrome, and  
 migraine headaches, among others. Success of treating fibromyalgia with a single  
 pharmacological agent has been characterized as modest and results of clinical  
 trials have been characterized as disappointing. It is believed that based on  
 current understanding of the mechanisms and pathways involved in fibromyalgia,  
 multiple agents will be required, aimed at the major symptoms of pain, disturbed  
 sleep, mood disturbances, and fatigue. Fibromyalgia patients are often sensitive to  
 side effects of medications, a characteristic perhaps related to the pathophysiology  
 of this disorder (Barkhuizen A, Rational and Targeted pharmacologic treatment of  
 fibromyalgia. Rheum Dis Clin N Am 2002; 28: 261-290; Leventhal LJ.  
 Management of fibromyalgia. Ann Intern Med 1999;131:850-8).